We have curated a list of phase 3 clinical trials that have an anticipated completion date in May 2025 in the United States. Once completed, it is required that the results be posted within one year of the primary completion date. These interventional clinical trials hold the promise of transforming treatment protocols for a myriad of conditions, potentially leading to updates of medical guidelines.
May 2025 Phase 3 Clinical Trials
| Primary Completion Date | Study Title With Link | Brief Summary | Conditions | Interventions |
|---|---|---|---|---|
| 5/1/2025 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. | Alopecia Areata | DRUG: CTP-543 |
| 5/7/2025 | Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis | Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis | DRUG: Saroglitazar Magnesium 1 mg DRUG: Saroglitazar Magnesium 2 mg DRUG: Placebo |
| 5/15/2025 | Fluvoxamine for Long COVID-19 | This trial is testing whether fluvoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois. | Long COVID | DRUG: Fluvoxamine |
| 5/16/2025 | Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee | An open-label, single-arm clinical trial to confirm the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in patients who have pain associated with osteoarthritis of the knee despite standard of care. | Osteoarthritis | DRUG: RTX-GRT7039 |
| 5/19/2025 | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) | The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744. | Asthma | BIOLOGICAL: GSK3511294 (Depemokimab) |
| 5/21/2025 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis | The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis. | Plaque Psoriasis, Scalp Psoriasis | DRUG: Guselkumab DRUG: Placebo |
| 5/31/2025 | Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies | Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies. | Hematological Malignancies | BIOLOGICAL: omidubicel |
| 5/31/2025 | Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis | A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist. | Infertility, Endometriosis | DRUG: Elagolix 200 MG OTHER: Placebo or SOC IVF |
| 5/31/2025 | Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil | The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH). | Primary Pulmonary Hypertension | DRUG: LIQ861 Inhaled Treprostinil |
And that’s a wrap on the phase 3 clinical trials with a primary completion date in May 2025. Be sure to check back for next month’s edition! In the meantime, explore more clinical trials and sign up for alerts to stay up to date with the latest published guidelines and research.
Copyright © 2025 Guideline Central, all rights reserved.